The chart below shows how PLXS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PLXS sees a -0.60% change in stock price 10 days leading up to the earnings, and a +1.37% change 10 days following the report. On the earnings day itself, the stock moves by -0.71%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Record Free Cash Flow: Plexus achieved record free cash flow of $194 million in Q4, contributing to a total of $341 million for fiscal 2024, more than double the previous record.
Operating Margin Achievement: Non-GAAP operating margin reached 6.2% in Q4, exceeding the guidance range and achieving the long-term goal one year ahead of schedule.
Strong Q4 Revenue Performance: Revenue for Q4 was $1.05 billion, surpassing guidance and reflecting strong demand across multiple market sectors, particularly aerospace and defense.
Manufacturing Program Wins: The company secured 26 manufacturing program wins worth $230 million in annual revenue during Q4, including significant contributions from the Healthcare Life Sciences sector.
Debt Reduction and Share Buyback: Plexus reduced total debt by $102 million in Q4 and $184 million for the fiscal year, while also completing a $50 million share repurchase program.
Negative
Healthcare Revenue Decline: Revenue in the Healthcare Life Sciences sector declined 17% for fiscal 2024 due to inventory corrections and demand softness, with expectations for a further decline of high single digits in fiscal Q1.
Industrial Sector Revenue Decline: The industrial sector experienced a 3% revenue decline for fiscal 2024, with expectations of a mid single-digit decline in fiscal Q1 due to ongoing demand instability and inventory corrections.
Operating Margin Guidance Decline: Despite achieving a non-GAAP operating margin of 6.2%, the guidance for fiscal Q1 indicates a decrease to a range of 5.7% to 6.1%, reflecting lower revenue and fixed cost leverage.
EMEA Q4 Performance Weakness: The EMEA region's fiscal Q4 wins were only $5,000,000, indicating weak demand and limited growth opportunities compared to other regions.
Revenue Growth Pause: The company anticipates a pause in sequential revenue growth for fiscal Q1, primarily due to the impact of pull-ins from fiscal Q4, which may hinder overall growth projections for fiscal 2025.
Earnings call transcript: Plexus Q4 2024 beats guidance, stock dips
PLXS.O
-1.66%